Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mission Biocapital
BioCentury | Dec 19, 2024
Finance
Siteone’s $100M to bring non-opioid pain therapy into the clinic
BioCentury’s Venture Report also features a new European VC fund and $60M for Akamis Bio
BioCentury | Nov 23, 2024
Finance
ATB’s €54M series A among largest ever in Belgium
BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
BioCentury | May 23, 2024
Finance
Venture Report: Versant revisits build-to-buy model with obesity play SixPeaks
Plus: Progentos’ launch; series B rounds for AltruBio, Pheon and Grey Wolf; a series A for Vienna-based Ygion; and more
BioCentury | Mar 8, 2024
Finance
Trio of large, crossover-backed rounds lead week’s deals
Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M
BioCentury | Oct 6, 2023
Regulation
Oct. 5 Quick Takes: FDA panel declines to back Lumakras
Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more
BioCentury | Apr 4, 2023
Regulation
April 3 Quick Takes: Padcev label expanded to first-line urothelial cancer
Plus: Ascendis’ market cap melts as thyroid program hits FDA snag and updates from Apellis, Vedere and Vertex-CRISPR
BioCentury | Mar 15, 2023
Emerging Company Profile
Backed by broad syndicate, Mediar takes downstream approach to fibrosis
Academic spinout has drawn $105M to advance first-in-class therapies against three targets
BioCentury | Sep 1, 2022
Management Tracks
Industry needs to broaden the talent bridge into biopharma
Courting talent in new places and displaying a range of career paths is essential to building a strong, diverse pipeline for the future
BioCentury | Jun 15, 2022
Market Access
June 14 Quick Takes: ICER weighs in on Amylyx’s ALS treatment
Plus EQRx’s first regulatory submission, WHO to discuss monkeypox status and updates from PureTech, Tilt and more
BioCentury | Jun 7, 2022
Finance
Zurich-based ImmunOs taps U.S.-EU syndicate for $74M series B, expands footprint
Swiss immuno-oncology start-up building presence in Maryland as lead HLA-derived program nears clinic
Items per page:
1 - 10 of 27